|

PD-1 inhibitor based immunotherapy Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

  • Ruijin Hospital1

Indications

  • Total Neoadjuvant Treatment1
  • Rectal Cancer, Radiotherapy1
  • Total Neoadjuvant Therapy1
  • Rectal Adenocarcinoma1
  • Targeted Therapy1

Other1 trial

SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.